NUTRA PHARMA CORP
NPHC evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Market Cap:
- $716K
- Lead Asset:
- nyloxin (Approved)
What it means
What to watch
Prepared research question
What matters most for NPHC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NPHC
Nutra Pharma Corp. is a biotechnology company focused on developing treatments for multiple sclerosis and pain management, currently holding orphan drug designation for its lead candidate RPI-78M but facing significant financial challenges and a going concern warning.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$716K
Cash Runway
—
Lead Asset
nyloxin (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 2 clinical trials for NUTRA PHARMA CORP.
Nutra Pharma Corp. is a biotechnology company focused on developing treatments for multiple sclerosis and pain management, currently holding orphan drug designation for its lead candidate RPI-78M but facing significant financial challenges and a going concern warning.
- Received FDA Orphan designation for RPI-78M for Pediatric Multiple Sclerosis [sec_mda · as of 2026-05-20].
- As of December 31, 2025, the company reported cash of $12,181 and a working capital deficit of $16,813,637 [sec_mda · as of 2026-05-20].
- Stockholders' equity was -$21.2M as of June 30, 2026, with a net loss of $3.9M for the six months then ended [sec].
- The company is currently preparing for a pre-IND meeting with the FDA for a Phase I/II study in Pediatric MS, aiming to begin in early 2026 [sec_mda · as of 2026-05-20].
- Operations are funded through product sales, convertible notes, and promissory notes; $1,051,805 was raised from convertible notes in 2025 [sec_mda · as of 2026-05-20].
What works
- Lead drug candidate RPI-78M has received FDA Orphan Drug Designation for Pediatric Multiple Sclerosis, which may shorten clinical timelines and allow Fast Track approval [sec_mda · as of 2026-05-20].
- The company has existing product sales from Nyloxin and Pet Pain-Away, providing some revenue stream to support operations [sec_mda · as of 2026-05-20].
What to weigh
- Nutra Pharma has a history of net losses and an accumulated deficit of over $16.8M as of December 31, 2025 [sec_mda · as of 2026-05-20].
- The company states it does not have sufficient cash to sustain operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-05-20].
- Common stock is traded on the OTC Expert Market, limiting liquidity and access to capital markets [sec_mda · as of 2026-03-11].
- The company relies heavily on debt financing, with $1.34M outstanding as of December 31, 2025 from related parties [sec_mda · as of 2026-05-20].
From the filings
Quoted directly from source documents.
Recertification of laboratory facility
“In November 2014, we announced the recertification of our laboratory facility as the first step in re-engaging our drug development activities.”
SEC MD&A · May 20, 2026
Cash position and working capital deficit
“As of December 31, 2025, we had $12,181 in cash and owed approximately $5.10 million in vendor payables and accrued expenses.”
SEC MD&A · May 20, 2026
Goal for Phase I/II study start
“Our goal is to begin the study in early 2026.”
SEC MD&A · May 20, 2026
Substantial doubt about going concern
“we currently do not have sufficient cash to sustain our operations for the next 12 months and will require additional financing or an increase in sales in order to execute our operating plan and continue as a going concern.”
SEC MD&A · February 17, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Company lacks sufficient cash to sustain operations for 12 months [sec_mda · as of 2026-05-20].
- Stock liquidity risk
- Dependence on related-party debt — Outstanding loans from former CEO's companies total $1.34M, with uncertain terms [sec_mda · as of 2026-05-20].
- Regulatory and development risk — RPI-78M is still in pre-clinical stage; FDA approval is uncertain and costly [sec_mda · as of 2026-05-20].
What to watch
- Pre-IND meeting with FDA for RPI-78M Phase I/II protocol in Pediatric MS [sec_mda · as of 2026-05-20].
- Ability to raise additional financing to fund operations beyond 12 months [sec_mda · as of 2026-05-20].
- Revenue growth from Nyloxin and Pet Pain-Away to reduce reliance on debt [sec_mda · as of 2026-05-20].
- Any updates on stock exchange listing or OTC market status [sec_mda · as of 2026-03-11].
Sources: SEC MD&A · Generated September 13, 2026 · How we verify sources →
Run NUTRA PHARMA CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NUTRA PHARMA CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$4M
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for NUTRA PHARMA CORP?
Nutra Pharma Corp. is a biotechnology company focused on developing treatments for multiple sclerosis and pain management, currently holding orphan drug designation for its lead candidate RPI-78M but facing significant financial challenges and a going concern warning.
What is NUTRA PHARMA CORP's lead drug candidate?
NUTRA PHARMA CORP's most advanced tracked candidate is nyloxin (Approved) for Moderate to severe chronic pain.
Who is the CEO of NUTRA PHARMA CORP?
Dr. Michael D. Flax D.D.S., M.S., P.A. is the chief executive officer of NUTRA PHARMA CORP (NPHC).
Where is NUTRA PHARMA CORP headquartered?
NUTRA PHARMA CORP (NPHC) is headquartered in Boca Raton, FL, United States.
What therapeutic areas does NUTRA PHARMA CORP focus on?
NUTRA PHARMA CORP develops therapies across Neurology, Immunology, Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.